The SOLO-1 trial demonstrated the benefit of which PARP inhibitor as maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer after first-line platinum-based chemotherapy?
- A Niraparib
- B Rucaparib
- C Olaparib ✓
- D Talazoparib
Correct answer: C. Olaparib
Explanation
The SOLO-1 trial (NEJM 2018) established olaparib maintenance therapy after first-line platinum-based chemotherapy in patients with newly diagnosed advanced (Stage III/IV) BRCA1/2-mutated ovarian cancer. Olaparib significantly extended progression-free survival (not reached vs 13.8 months for placebo at 3 years) and became the standard of care for this indication. Niraparib is used in the PRIMA trial setting for HRD-positive patients.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.